<code id='BD8F1B0AD4'></code><style id='BD8F1B0AD4'></style>
    • <acronym id='BD8F1B0AD4'></acronym>
      <center id='BD8F1B0AD4'><center id='BD8F1B0AD4'><tfoot id='BD8F1B0AD4'></tfoot></center><abbr id='BD8F1B0AD4'><dir id='BD8F1B0AD4'><tfoot id='BD8F1B0AD4'></tfoot><noframes id='BD8F1B0AD4'>

    • <optgroup id='BD8F1B0AD4'><strike id='BD8F1B0AD4'><sup id='BD8F1B0AD4'></sup></strike><code id='BD8F1B0AD4'></code></optgroup>
        1. <b id='BD8F1B0AD4'><label id='BD8F1B0AD4'><select id='BD8F1B0AD4'><dt id='BD8F1B0AD4'><span id='BD8F1B0AD4'></span></dt></select></label></b><u id='BD8F1B0AD4'></u>
          <i id='BD8F1B0AD4'><strike id='BD8F1B0AD4'><tt id='BD8F1B0AD4'><pre id='BD8F1B0AD4'></pre></tt></strike></i>

          
          WSS
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion